 |
|
|
| |
A Phase IIa, open-label study to assess the antiviral activity of TMC435
monotherapy in patients infected with HCV genotypes 2-6
|
| |
| |
Reported by Jules Levin
AASLD Nov 2 2010 Boston
C. Moreno,1 T. Berg,2 T. Tanwandee,3 S. Thongsawat,4 H. Van Vlierberghe,5 S. Zeuzem,6 O. Lenz,7 M. Peeters,7 V. Sekar,8 G. De Smedt7
1Department of Gastroenterology and Hepatopancreatology, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium; 2Department of Hepatology, Clinic of Gastroenterology and Rheumatology, University Clinic Leipzig, Leipzig, Germany; 3Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; 4Chiang Mai University, Chiang Mai, Thailand; 5Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium; 6Department of Medicine I, J.W. Goethe University Hospital, Frankfurt, Germany; 7Tibotec, Beerse, Belgium; 8Tibotec Inc., Titusville, NJ, USA
Disclosure: C. Moreno is an investigator for Roche, Gilead, Schering Plough, Pfizer, and Tibotec, is a speaker for Schering Plough and BMS, and is a consultant/advisor for Janssen-Clegg and Schering Plough; T. Berg is a consultant and member of a speaker bureau for Roche, Schering Plough, Vertex, Janssen-Cilag, Tibotec, Novartis,
BMS, and Gilead; T. Tanwandee has received research grant support from Roche, MSD, Novartis, Human Genome Science, Celsion, and Tibotec; S. Thongsawat and H. Van Vlierberghe have no disclosures to declare; S. Zeuzum is a consultant for Abbott, Achillion, Anadys, BMS, Gilead, GSK, HGS, Merck, Novartis, Pharmasset, Roche, Santaris, Vertex, and Tibotec; O. Lenz, M. Peeters, V. Sekar, and G. De Smedt are all employees of Tibotec.
|
| |
|
|
|
|
|
